Clinical experience and psychometric properties of the Cardiff Acne Disability Index (CADI).

Like Comment
The Cardiff Acne Disability Index (CADI) is a questionnaire designed to measure the quality of life (QoL) of teenagers and young adults with acne. It has been used clinically and within therapeutic research globally. This review aims to appraise all published data regarding the clinical and research experience of CADI, its psychometric properties and validation, from its publication in 1992 until September 2020, into a single reference source. A literature search was conducted using Medline via Ovid, PubMed, EBSCOhost, Web of Science and Scopus. All full articles in the English language were included. Ninety-six clinical studies were identified and analysed. The CADI has been used in 44 different countries, including four multinational studies, and has validated translations in 25 languages. Twenty-nine therapeutic interventions have used CADI, demonstrating its responsiveness to change. Fourteen studies have assessed reliability through test-retest and internal consistency studies. Fifty-seven studies have demonstrated aspects of its validity through correlation to other measures and five studies have investigated the dimensionality of CADI. There is evidence of high internal consistency, test-retest reliability, responsiveness to change and significant correlation with other objective measures. The minimal clinically important difference and validated score meaning bands have not yet been reported. This information is needed to improve the interpretability of CADI scores for clinical use and in research. The authors of CADI have also rephrased question two of the measure to ensure inclusivity.


View the full article @ The British journal of dermatology


Get PDF with LibKey
Authors: Y T Abdelrazik, F M Ali, M S Salek, A Y Finlay

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
6577 Contributions
2 Followers
0 Following